Damora Therapeutics, Inc.

Damora Therapeutics, Inc. (GLTO) priced its initial public offering on Oct 30, 2020 at $15.00 per share, within its $14.00–$16.00 range, raising $85M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $368.8M. BofA Securities was lead-left underwriter, joined by Leerink Partners and Credit Suisse. Goodwin Procter advised the company and Mintz advised the underwriters.

At its 2020 IPO, Galecto, Inc. (now Damora Therapeutics, Inc.) was a clinical-stage biotechnology company developing treatments for fibrosis and related diseases, including cancer. Its initial focus was small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2).

Status

IPO

Ticker

GLTO

Exchange

Nasdaq Global Select

Priced

Oct 30, 2020

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$85M

Market cap at IPO price

$368.8M

First filed

Oct 7, 2020

Underwriters

BofA Securities, Leerink Partners and Credit Suisse

Company counsel

Goodwin Procter

Underwriters' counsel

Mintz

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.